NK cell populations in collagen vascular disease

Clinical and Experimental Rheumatology

Volumn 30, Issue 5, 2012, Pages 693-699

  Papakosta, D ^a   Manika, K ^a   Kyriazis, G ^a   Kontakiotis, T ^a   Zarogoulidis, K ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Bronchoalveolar lavage fluid (BALF); Collagen vascular diseases (CVDs)

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; BRONCHOSCOPE; BRONCHOSCOPY; CELL DENSITY; COLLAGEN DISEASE; COLLAGEN VASCULAR DISEASE; CONTROLLED STUDY; COUGHING; DYSPNEA; FEMALE; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOCYTE DIFFERENTIAL COUNT; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SPIROMETER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE SUBPOPULATION; VITAL CAPACITY; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTIGENS, CD19; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; COLLAGEN DISEASES; FEMALE; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; HUMANS; KILLER CELLS, NATURAL; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; RESPIRATORY FUNCTION TESTS; VASCULAR DISEASES; VITAL CAPACITY;

EID: 84870271344     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. LAMBLIN C, BERGOIN C, SAELENS T, WALLAERT B: Interstitial lung disease in collagen vascular disease. Eur Respir J 2001;18(Suppl. 32):69S-80S.
2. WOODHEAD F, WELLS AU, DESAI SR: Pulmonary Complications of Connective Tissue Diseases. Clin Chest Med 2008;29:149-64.
3. WELLS AU: Lung disease in association with connective tissue diseases. Eur Respir Mon 2000;14:137-64.
4. KLECH H, HUTTER C, COSTABEL U: Clinical guidelines and indications for bronchoalveolar lavage (BAL). Report of the European Society of pneumonology Task Group on BAL. Eur Respir J 1992;2:47-127.
5. WALLAERT B, HOORELBEKE A, SYBILLE Y, ROSSI GA: The central role of bronchoalveolar lavage in collagen-vascular disease. Clinical guidelines and indications for bronchoalveolar lavage (BAL). Eur Respir Rev 1992;2:64-8.
6. GONZALEZ-AMARO R, ALCOCER-VARELA J, ALARCON-SEGOVIA D: Natural killer cell activity in the systemic connective tissue diseases. J Rheumatol 1988;15:1223-8.
7. GREEN MR, KENNELL AS, LARCHE MJ et al.: Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 2005;141:165-73.
8. SIGAL LH: Basic science for the clinician 35: CD1, invariant NKT (iNKT) cells, and gammadelta T-cells. J Clin Rheumatol 2005;11:336-9.
9. RICCIERI V, PARISIG, SPADARO A et al:. Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol 2005;32:283-6.
10. TAKAGI D, IWABUCHI K, IWABUCH C et al:. Immunoregulatory defects of V alpha 24V+betall+NKT cells in the development of Wegener's granulomatosis and relapsing polychondritis. Clin Exp Immunol 2004;136:591-600.
11. ARNETT FC, EDWORTHY SM, BLOCH DA et al:. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. MASI AT, RODNAN GP, MEDSGER TAJ et al:. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
13. TAN EM, COHEN AS, FRIES JF et al:. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
14. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
15. VITALI C, BOMBARDIERI S, MOUTSOPOULOS HM et al:. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective action supported by the European Community. Arthritis Rheum 1993;36:340-7.
16. LEAVITT RY, FAUCI AS, BLOCH DA et al:. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
17. MILLER MR, HANKINSON J, BRUSASCO V et al:. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
18. KLECH H, POHL W: Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Respir J 1992;2:561-85.
19. BOUROS D, WELLS AU, NICHOLSON AG et al:. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581.
20. GUDBJORNSSON B, HALLGREN R, NETTELBLADT O et al.: Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren syndrome. Ann Rheum Dis 1994;53:574-9.
21. ANTONIOU KM, WELLS AU: Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 2008;20:686-91.
22. SALAFFI F, MANGANELLI P, CAROTTI et al:. A longitudinal study of pulmonary involvement in primary Sjögren' syndrome: relationship between alveolitis and subsequent lung changes on high-resolution computed tomography. Br J Rheumatology 1998;37:263-9.
23. + lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 2000;43:236-8.
24. GROEN H, ASLANDER M, BOOTSMA H et al:. Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus. Clin Exp Immunol 1993;94:127-33.
25. DOMAGALA-KULAWICK J, HOSER G, DOBOSZYNSKA A, KAWIAK J, DROSZCZ W: Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocyte phenotype and DLCO impairment. Respir Med 1998;92:1295-301.
26. HASEGAWA M: B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 2010;37:3-10.
27. LEASK A: B cell block: Is rituximab a new possible treatment for systemic sclerosis? Cell Commun Signal 2010;4:201-2.
28. NAGASAWA Y, TAKADA T, SHIMIZU T et al:. Inflammatory cells in lung disease associated with rheumatoid arthritis. Intern Med 2009;48:1209-17.
29. SALAFFI F, MANGANELLI P, CAROTTI M, BALDELLI S: The differing patterns of subclinical pulmonary involvement in connective tissue diseases as shown by application of factor analysis. Clin Rheumatol 2000;19:35-41.
30. ROBINSON BW, PINKSTON P, CRYSTAL RG: Natural killer cells are present in the normal lung but are functionally impotent. J Clin Invest 1984;74:942-50.
31. IZUMi Y, IDA H, HUANG M et al:. Characterization of peripheral natural killer cells in primary Sjögren syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med 2006;147:242-9.
32. HORIKAWA M, HASEGAWA M, KOMURA K et al:. Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killinfg activity. J Invest Dermatol 2005;125:731-7.
33. MIYAKE S, YAMAMUTA T: NKT cells and autoimmune diseases: understanding the complexity. Curr Top Microbiol Immunol 2007;314:251-67.
34. WU L, Van KAER L: Natural killer T cells and autoimmune disease. Curr Mol Med 2009;9:4-14.
35. YAMAMURA T, SAKUISHI K, ILLES Z, MIYAKE S: Understanding the behavior of invariant NKT cells in autoimmune disease. J Neuroimmunol 2007;191:8-15.
36. LINSEN L, THEWISSEN M, BAETEN K: Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th-1 phenotype in rheumatoid arthritis. Arthritis Res Ther 2005;7:493-502.
37. Van KAER L: Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol 2004;82:315-22.
38. GABRIEL L, MORLEY BJ, ROGERS NJ: The role of iNKT cells in the immunopathology of systemic lupus erythematosus. Ann N Y Acd Sci 2009;1173:435-41.
39. NOVAK J, LEHUEN A: Mechanism of regulation of autoimmunity by iNKT cells. Cytokine 2011;53:263-70.
40. MIYAKE S, YAMAMURA T: Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:315-22.
41. GRUBER R, PFORTE A, BEER B, RIETHMULLER G: Determination of gamma/delta and other T-lymphocyte subsets in bronchoalveolar lavage fluid and peripheral blood from patients with sarcoidosis and idiopathic fibrosis of the lung. APMIS 1996;104:199-205.
42. ESPOSITO I, PERNA F, PONTICIELLO A, PERELLA M, GILLI M, SANDURRI A: Natural killer cells in BAL and peripheral blood of patients with idiopathic pulmonary fibrosis (IPF). Int J Immunopathol Pharmacol 2005;18:541-5.
43. + natural killer cells in hypersensitivity pneumonitis. Chest 2007;132:1291-7.
44. PAPAKOSTA D, MANIKA K, KYRIAZIS G et al.: Bronchoalveolar lavage fluid eosinophils are correlated to natural killer cells in eosinophilic pneumonias. Respiration 2009;78:177-84.
45. PAPAKOSTA D, KYRIAZIS G, GIOULEKAS D et al:. Variations in alveolar cell populations, lymphocyte subsets and NK-cells in different stages of active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:21-6.